Effect of cyclophosphamide in active nonviral cirrhosis.

Abstract

The immunologic effects of cyclophosphamide were studied in 16 patients with active nonviral liver cirrhosis with a view to improving the pathogenetic treatment of these diseases. After months of cyclophosphamide administration first in doses of 100 mg/day (for 14 days) then in doses of 200 mg per week, the hypergammaglobulinemia present at entry was reduced significantly from 2.55 +/- 0.35 g/dl to 1.71 +/- 0.17 g/dl concomitantly with the proportional increase of the active suppressor T lymphocytes, from 29.3 +/- 3.59% to 38.0 +/- 2.1%. The use of smaller doses of cyclophosphamide, i.e., 200 mg/week, allowed the maintenance of its immunosuppressive properties and prevented its side effects.

• Authors: P Szanto, L Stanciu, E Togănel, D Dejica
• Journal: Romanian journal of internal medicine = Revue roumaine de medecine interne (Rom J Intern Med) 1991 Jul-Dec Vol. 29 Issue 3-4 Pg. 205-10 ISSN: 1220-4749 [Print] Germany
• PMID: 1784950 (Publication Type: Journal Article)

Chemical References

• Adjuvants, Immunologic
• Cyclophosphamide

Topics

• Adjuvants, Immunologic (administration & dosage)
• Administration, Oral
• Adult
• Aged
• Cyclophosphamide (administration & dosage)
• Female
• Humans
• Hypergammaglobulinemia (drug therapy, immunology)
• Liver Cirrhosis (drug therapy, immunology)
• Liver Cirrhosis, Alcoholic (drug therapy, immunology)
• Male
• Middle Aged
• T-Lymphocytes (drug effects, immunology)
• Time Factors